CRISPR Therapeutics AG (CRSP) Free Cash Flow (2015 - 2026)

CRISPR Therapeutics AG has disclosed Free Cash Flow across 12 years of filings, most recently posting -$109.4 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$109.4 million, down 102.02% year-over-year; the trailing twelve-month figure through Mar 2026 was -$401.2 million (down 31.06% YoY), and the FY2025 annual result was -$345.9 million, down 142.03% from the prior year.
• Free Cash Flow came in at -$109.4 million for Q1 2026 at CRISPR Therapeutics AG, down from -$93.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $109.0 million in Q1 2024 to a low of -$161.0 million in Q2 2022.
• The 5-year median for Free Cash Flow is -$96.3 million (2024), against an average of -$82.4 million.
• Peak annual rise in Free Cash Flow reached 1668.26% in 2024, while the deepest fall reached 155.23% in 2024.
• CRISPR Therapeutics AG's Free Cash Flow stood at -$145.6 million in 2022, then soared by 33.51% to -$96.8 million in 2023, then jumped by 49.86% to -$48.5 million in 2024, then sank by 91.75% to -$93.1 million in 2025, then dropped by 17.55% to -$109.4 million in 2026.
• The last three Free Cash Flow figures came in at -$109.4 million (Q1 2026), -$93.1 million (Q4 2025), and -$84.7 million (Q3 2025), per Business Quant data.